Not Yet RecruitingPhase 2ACTRN12611000306910

Efficacy of Seasonal Influenza Vaccine (SIV) or “Flu vaccine” in cancer patients undergoing chemotherapy.

Phase II trial to study the efficacy of seasonal influenza vaccine in cancer patients undergoing chemotherapy

Sponsor

Flinders Medical centre

Enrollment

50 participants

Start Date

Mar 28, 2011

Study Type

Interventional

Conditions

Efficacy of flu vaccine in cancer patient undergoing chemotherapy

Summary

This study is designed to study the efficacy of flu vaccine in patients with cancer undergoing chemotherapy, by assessing the antibody response to flu vaccination to see if they reach 'protective' levels Who is it for? You may join this study if you are over 18 years of age, have a histologically or cytologically confirmed neoplasm, and are about to start chemotherapy or currently already on chemotherapy. Trial Details Patients receiving chemotherapy will be given 0.5 ml of the trivalent seasonal flu vaccine for 2011, intramuscular or deep subcutaneous, approximately 7 days before the next dose of chemotherapy. This will be a once off intervention. Blood will be drawn at baseline, 3-4 weeks, 6-7 weeks and 6 months after the vaccine dose and will be analysed for Influenza antibody levels. The aim of this study is to investigate the efficacy of flu vaccine in cancer patient undergoing chemotherapy.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests how effective the seasonal flu vaccine is in cancer patients undergoing chemotherapy. It is for adults over 18 with a confirmed cancer diagnosis who are starting or already on chemotherapy. People who have already had the flu vaccine this season, are allergic to the vaccine or eggs, or have a history of Guillain-Barre Syndrome are excluded.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Efficacy of flu vaccine. Patients receiving chemotherapy will be given 0.5 ml of the trivalent seasonal flu vaccine for 2011, intramuscular or deep sub cutaneous, approximately 7 days before the next

Efficacy of flu vaccine. Patients receiving chemotherapy will be given 0.5 ml of the trivalent seasonal flu vaccine for 2011, intramuscular or deep sub cutaneous, approximately 7 days before the next dose of chemotherapy. This will be a once off intervention. Blood will be drawn at baseline, 3-4 weeks, 6-7 weeks and 6 months after the vaccine dose and will be analysed for Influenza antibody levels.

Locations(1)

SA, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000306910